What is your second line therapy for patients with EGPA with mainly pulmonary and sinonasal features who did not respond to mepolizumab 300 mg/month and still require high doses of steroid?   

This is a great question without a clear answer in the literature. One of the reasons that there is a lack of literature for this specific patient population is that most previous studies have not specifically looked at patients with primarily eosinophilic manifestations. The one notable exception i...

Guidelines for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) are based on limited data from clinical trials or even protocol-based cohorts. However, there are several ongoing and planned randomized controlled trials that will likely help inform new approaches to treating this...